Photodiagnosis and photodynamic therapy · 2026
Efficacy of red light for myopia control from age 2 to 24 with diverse treatment periods: A real-world study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yanxian, Wu Yue, Wang Lili, Zhu Zhuoting, Shang Xianwen, Li Jijing, Ni Yao, Chen Yanping, Jiang Feng, Xiong Ruilin, Yang Xiao, He Mingguang, Zeng Junwen
Аннотация
PURPOSE: To explore the age-specific efficacy, long-term outcomes and safety of RLRL therapy in real-world clinical settings.
METHODS: In the prospective, multi-center, real-world cohort, 2825 participants who underwent low-level red light (RLRL) therapy for myopia control were recruited from 20 hospitals in China. Axial length (AL), spherical equivalent refraction (SER), best-corrected visual acuity (BCVA), compliance, and adverse events were recorded at baseline and each visit. Follow-up duration was stratified into four periods (≤ 6, 7-12, 13-24, and 25-36 months). Efficacy was estimated as the annual changes of AL using longitudinal linear mixed-effect model.
RESULTS: AL increased slightly in children aged 2-7 and 8-12 years, but remained stable in those aged 13-24 years. During the first 6 months, annual axial length (AL) changes reached -0.18, -0.29, and -0.72 mm for the 2-7, 8-12, and 13-24 group, and shifted to 0.14, 0.06, and -0.01 mm with 25-36 months of treatment. Multivariable analyses identified larger baseline AL (β = 0.72, p < 0.001) and the oldest age group (β = 0.82, p = 0.009) as independent predictors of AL shortening, while combining orthokeratology offered no additional benefit (p > 0.05). Adverse events were infrequent (0.21%).
CONCLUSIONS: RLRL therapy is an effective and well-tolerated approach for myopia control across a broad age range and up to 36 months, showing sustained efficacy and favorable safety in real-world clinical settings.
METHODS: In the prospective, multi-center, real-world cohort, 2825 participants who underwent low-level red light (RLRL) therapy for myopia control were recruited from 20 hospitals in China. Axial length (AL), spherical equivalent refraction (SER), best-corrected visual acuity (BCVA), compliance, and adverse events were recorded at baseline and each visit. Follow-up duration was stratified into four periods (≤ 6, 7-12, 13-24, and 25-36 months). Efficacy was estimated as the annual changes of AL using longitudinal linear mixed-effect model.
RESULTS: AL increased slightly in children aged 2-7 and 8-12 years, but remained stable in those aged 13-24 years. During the first 6 months, annual axial length (AL) changes reached -0.18, -0.29, and -0.72 mm for the 2-7, 8-12, and 13-24 group, and shifted to 0.14, 0.06, and -0.01 mm with 25-36 months of treatment. Multivariable analyses identified larger baseline AL (β = 0.72, p < 0.001) and the oldest age group (β = 0.82, p = 0.009) as independent predictors of AL shortening, while combining orthokeratology offered no additional benefit (p > 0.05). Adverse events were infrequent (0.21%).
CONCLUSIONS: RLRL therapy is an effective and well-tolerated approach for myopia control across a broad age range and up to 36 months, showing sustained efficacy and favorable safety in real-world clinical settings.